These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

797 related articles for article (PubMed ID: 12524460)

  • 1. Cardiac hypertrophy: the good, the bad, and the ugly.
    Frey N; Olson EN
    Annu Rev Physiol; 2003; 65():45-79. PubMed ID: 12524460
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Myocyte hypertrophy and apoptosis: a balancing act.
    van Empel VP; De Windt LJ
    Cardiovasc Res; 2004 Aug; 63(3):487-99. PubMed ID: 15276474
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiac hypertrophy: a risk factor for QT-prolongation and cardiac sudden death.
    Kang YJ
    Toxicol Pathol; 2006; 34(1):58-66. PubMed ID: 16507545
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Calcineurin/NFAT coupling participates in pathological, but not physiological, cardiac hypertrophy.
    Wilkins BJ; Dai YS; Bueno OF; Parsons SA; Xu J; Plank DM; Jones F; Kimball TR; Molkentin JD
    Circ Res; 2004 Jan; 94(1):110-8. PubMed ID: 14656927
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changes in the genetic expression of membrane proteins as a determinant of myocardial dysfunction.
    Swynghedauw B
    Acta Cardiol; 1996; 51(4):301-14. PubMed ID: 8888889
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The PTHrP/PTH.1-R bioregulation system in cardiac hypertrophy: possible therapeutic implications.
    Halapas A; Diamanti-Kandarakis E; Kremastinos D; Koutsilieris M
    In Vivo; 2006; 20(6B):837-44. PubMed ID: 17203776
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Physiologic versus pathologic hypertrophy and the pressure-overloaded myocardium.
    Weber KT; Clark WA; Janicki JS; Shroff SG
    J Cardiovasc Pharmacol; 1987; 10 Suppl 6():S37-50. PubMed ID: 2485029
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanotransduction in cardiac hypertrophy and failure.
    Lyon RC; Zanella F; Omens JH; Sheikh F
    Circ Res; 2015 Apr; 116(8):1462-1476. PubMed ID: 25858069
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hypoxia-driven glycolytic and fructolytic metabolic programs: Pivotal to hypertrophic heart disease.
    Mirtschink P; Krek W
    Biochim Biophys Acta; 2016 Jul; 1863(7 Pt B):1822-8. PubMed ID: 26896647
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytoplasmic signaling pathways that regulate cardiac hypertrophy.
    Molkentin JD; Dorn GW
    Annu Rev Physiol; 2001; 63():391-426. PubMed ID: 11181961
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel molecular targets in the treatment of cardiac hypertrophy.
    Luedde M; Katus HA; Frey N
    Recent Pat Cardiovasc Drug Discov; 2006 Jan; 1(1):1-20. PubMed ID: 18221071
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Molecular biology of adaptive myocardial hypertrophy].
    Schunkert H; Riegger AJ
    Dtsch Med Wochenschr; 1992 Sep; 117(37):1406-12. PubMed ID: 1355424
    [No Abstract]   [Full Text] [Related]  

  • 13. Time course alterations of myocardial endothelin-1 production during the formation of exercise training-induced cardiac hypertrophy.
    Iemitsu M; Maeda S; Otsuki T; Goto K; Miyauchi T
    Exp Biol Med (Maywood); 2006 Jun; 231(6):871-5. PubMed ID: 16741015
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tapping the brake on cardiac growth-endogenous repressors of hypertrophic signaling.
    Leenders JJ; Pinto YM; Creemers EE
    J Mol Cell Cardiol; 2011 Aug; 51(2):156-67. PubMed ID: 21586293
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of heat shock transcriptional factor 1 and heat shock proteins in cardiac hypertrophy.
    Toko H; Minamino T; Komuro I
    Trends Cardiovasc Med; 2008 Apr; 18(3):88-93. PubMed ID: 18436146
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Is secondary myocardial hypertrophy a physiological or pathological adaptive mechanism?].
    Krayenbühl HP
    Z Kardiol; 1982 Aug; 71(8):489-96. PubMed ID: 6215776
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fibroblast growth factor 2 isoforms and cardiac hypertrophy.
    Kardami E; Jiang ZS; Jimenez SK; Hirst CJ; Sheikh F; Zahradka P; Cattini PA
    Cardiovasc Res; 2004 Aug; 63(3):458-66. PubMed ID: 15276471
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Collagen in the hypertrophied, pressure-overloaded myocardium.
    Weber KT; Janicki JS; Pick R; Abrahams C; Shroff SG; Bashey RI; Chen RM
    Circulation; 1987 Jan; 75(1 Pt 2):I40-7. PubMed ID: 2947751
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Myocardial response to stress in cardiac hypertrophy and heart failure: effect of antihypertensive drugs.
    Sen S
    Ann N Y Acad Sci; 1999 Jun; 874():125-33. PubMed ID: 10415526
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular mechanisms that control interstitial fibrosis in the pressure-overloaded heart.
    Creemers EE; Pinto YM
    Cardiovasc Res; 2011 Feb; 89(2):265-72. PubMed ID: 20880837
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.